FCGR2B and metabolic dysfunction-associated steatotic liver disease: Another ligand of FcγRIIb, fibrinogen-like protein 2 (FGL2), was found to be increased in NAFLD patients demonstrating severe forms of NAFLD, suggesting a decrease in FcγRIIb expression (Colak et al., 2011).